GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » EPS without NRI

Black Diamond Therapeutics (Black Diamond Therapeutics) EPS without NRI : $-1.66 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics EPS without NRI?

Black Diamond Therapeutics's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.35. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.66.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 2.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -29.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Black Diamond Therapeutics's EPS without NRI or its related term are showing as below:

BDTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.8   Med: -47.55   Max: 2.8
Current: 2.8

During the past 7 years, Black Diamond Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 2.80% per year. The lowest was -75.80% per year. And the median was -47.55% per year.

BDTX's 3-Year EPS without NRI Growth Rate is ranked worse than
53.28% of 1297 companies
in the Biotechnology industry
Industry Median: 5.5 vs BDTX: 2.80

Black Diamond Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.66.

Black Diamond Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.66.


Black Diamond Therapeutics EPS without NRI Historical Data

The historical data trend for Black Diamond Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics EPS without NRI Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.88 -2.05 -3.47 -2.58 -1.88

Black Diamond Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.52 -0.45 -0.34 -0.35

Competitive Comparison of Black Diamond Therapeutics's EPS without NRI

For the Biotechnology subindustry, Black Diamond Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Black Diamond Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's PE Ratio without NRI falls into.



Black Diamond Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Black Diamond Therapeutics  (NAS:BDTX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Black Diamond Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, 14th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani director, 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein director, officer: See Remarks OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov officer: CHIEF MEDICAL OFFICER C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck officer: CHIEF SCIENTIFIC OFFICER C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon director
Mark A. Velleca director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch officer: See Remarks C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451

Black Diamond Therapeutics (Black Diamond Therapeutics) Headlines

From GuruFocus

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-05-2023